Get the Stockscreener App
1.02
3.82%
0.0375
After Hours:
1.09
0.07
+6.86%
Estrella Immunopharma Inc stock is traded at $1.02, with a volume of 34,914.
It is up +3.82% in the last 24 hours and down -10.53% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
See More
Previous Close:
$0.9825
Open:
$1.03
24h Volume:
34,914
Relative Volume:
0.44
Market Cap:
$43.89M
Revenue:
-
Net Income/Loss:
$-13.06M
P/E Ratio:
-2.8563
EPS:
-0.3571
Net Cash Flow:
$-1.79M
1W Performance:
-0.97%
1M Performance:
-10.53%
6M Performance:
-25.55%
1Y Performance:
+15.91%
1-Day Range:
$0.95
$1.03
1-Week Range:
$0.95
$1.09
52-Week Range:
$0.78
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.02 | 44.76M | 0 | -13.06M | -1.79M | -0.3571 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026 - Minichart
Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Estrella Immunopharma, Inc.(NasdaqCM: ESLA) added to Russell 3000E Value Benchmark - marketscreener.com
Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA) - TradingView
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc - TradingKey
Estrella Immunopharma Inc (ESLAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLAW) Institutional Confidence - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Navigates Clinical DevelopmentEarnings Surprise Stocks - newsline.com
Estrella Immunopharma (ESLA) Edges Higher Amid Broader Biotech SentimentWyckoff Accumulation - newsline.com
ESLAW Warrants Slide 13% as Support at $0.10 Faces Critical TestStop Hunt - newsline.com
ESLA Q1 2026 Earnings: Wider Loss Than Expected Amid Pre-Revenue Development StageEPS Revision Trend - newsline.com
ESLA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock Rises 10.6%Earnings Sentiment Score - newsline.com
ESLA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-revenue Biotech Continues DevelopmentEarnings Revision Report - The Legal Advocate
Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.13 – Consolidation Narrows Trading RangeAD Line Divergence - newsline.com
Estrella Immunopharma (ESLA) Edges Lower Near Support as Biotech Sector Faces HeadwindsMutual Fund Flow - The Legal Advocate
ESLAW Surges 22.52%: Estrella Immunopharma Warrant Breaks Above SupportVolatility Surface - The Legal Advocate
Estrella Immunopharma Inc. (ESLA) Shows Modest Uptick Amid Sector StabilityLinear Regression - The Legal Advocate
Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor - Stock Titan
Estrella Immunopharma Warrant (ESLAW) Surges 18.85% to $0.10, Faces Key Resistance at $0.11Volume Breadth - The Legal Advocate
Estrella Immunopharma (ESLA) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Modest Stock GainLow Growth Earnings - Newser
ESLA Q1 2026 Earnings: Wider-Than-Expected Loss and No Revenue Highlight Development-Stage Challenges - newsline.com
Estrella Immunopharma (ESLA) Q1 2026 Earnings Slump: EPS Falls Short of $-0.18 TargetHigh Interest Stocks - Newser
Estrella Immunopharma, Inc. 2026 Q1 Financial Report: Key Financials, Related Party Transactions, and R&D Update - Minichart
Estrella Immunopharma (ESLA) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Growth Rate - Newser
Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma (ESLA) Stock Analysis: Falls -6.22%, Watching $1.07 2026-05-15Popular Market Picks - newser.com
[SCHEDULE 13G] Estrella Immunopharma, Inc. Passive Investment Disclosure (>5%) - Stock Titan
TradingKey - TradingKey
The quiet positioning of Estrella (ESLAW) nobody discusses (Moonwalks) 2026-05-08Bullish Pattern - newser.com
Estrella Immunopharma (ESLA) Q1 loss deepens, EPS miss of 90.6 percent rattles investor confidence.Special Dividend Alert - The Legal Advocate
Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - BioSpace
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Estrella Immunopharma Inc Stock (ESLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xu Jiandong | Chief Financial Officer |
Sep 22 '25 |
Buy |
1.16 |
1,000 |
1,160 |
16,700 |
| Xu Jiandong | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.04 |
100 |
104 |
264,588 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):